Agendia Presents Data Supporting Predictive Claim For Breast Cancer Dx | GenomeWeb
This article has been updated from a prior version to include detatils on the price of Herceptin provided by a Genentech spokesperson.
At the San Antonio Breast Cancer Symposium last week, Agendia presented new clinical trial data for its MammaPrint breast cancer recurrence test that it claims supports expanding the assay’s indication to include predicting chemotherapy response.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.